The capital raise will also support debt repayment or prepayment, improving the company's debt-to-equity ratio and overall financial resilience
The new facility combines advanced technology, enhanced capacity, and holistic care, reaffirming HCG’s commitment to accessible, world-class oncology in Gujarat
DESTINY-Breast09 Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive metastatic patient population versus current 1st-line standard of care
Blenrep combinations could redefine treatment as early as first relapse where more effective options are needed
Genomics is transforming the future of modern medicine and treatment modalities across specialties
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
Jobevne is a vascular endothelial growth factor (VEGF) inhibitor that binds with VEGF and blocks the interaction with its receptors to prevent angiogenesis
Shilpa’s product has been approved as a generic version to the innovator - Chantix Tablets, 0.5 mg and 1 mg, of PF Prism C.V. (PF Prism)
Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone
Subscribe To Our Newsletter & Stay Updated
